{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=warfarin&page=2",
    "query": {
      "intervention": "warfarin",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=warfarin&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T01:18:48.210Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04736719",
      "title": "Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19002,
      "start_date": "2020-09-22",
      "completion_date": "2021-02-18",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04736719"
    },
    {
      "nct_id": "NCT05891119",
      "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Caffeine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Rocatinlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-06-03",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 7,
      "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Dilworth",
          "state": "Minnesota"
        },
        {
          "city": "Camp Hill",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891119"
    },
    {
      "nct_id": "NCT01349712",
      "title": "Study to Test the Accuracy of a Prototype Handheld PT/INR Device",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Blood Coagulation Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Universal Biosensors Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2011-05",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2011-05-09",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 1,
      "location_summary": "Batesville, Arkansas",
      "locations": [
        {
          "city": "Batesville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349712"
    },
    {
      "nct_id": "NCT05445232",
      "title": "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "LY3437943",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2022-07-08",
      "completion_date": "2023-02-24",
      "has_results": false,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05445232"
    },
    {
      "nct_id": "NCT05085405",
      "title": "Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Upper Gastrointestinal Bleeding"
      ],
      "interventions": [
        {
          "name": "Clinician notification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification with Nurse Facilitation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification / Patient Activation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Notification with Nurse Facilitation / Patient Activation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-10-11",
      "completion_date": "2022-01-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05085405"
    },
    {
      "nct_id": "NCT00465270",
      "title": "Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cryptogenic Stroke"
      ],
      "interventions": [
        {
          "name": "AMPLATZER PFO Occluder",
          "type": "DEVICE"
        },
        {
          "name": "Standard of Care - Medical Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 980,
      "start_date": "2003-08",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-02-18",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00465270"
    },
    {
      "nct_id": "NCT02090075",
      "title": "Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "apixaban",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 66,
      "start_date": "2014-09",
      "completion_date": "2017-04-05",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02090075"
    },
    {
      "nct_id": "NCT02647086",
      "title": "Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-12",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-22",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02647086"
    },
    {
      "nct_id": "NCT00504556",
      "title": "A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Edoxaban (DU-176b)",
          "type": "DRUG"
        },
        {
          "name": "warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1146,
      "start_date": "2007-06",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 22,
      "location_summary": "Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00504556"
    },
    {
      "nct_id": "NCT01561937",
      "title": "Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Haemostasis",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-09-18T01:18:48.210Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561937"
    }
  ]
}